drugset / Trial / NCT02782897

Intravenous Immunoglobulin for Acute Intracranial Hemorrhage

NCT02782897

Phase 2 Unknown 60 enrolled Wei Wang
Non-randomizedParallel-groupSingle-blindTreatment

Summary

This pilot study aims to investigate whether intravenous immunoglobulin is safe and effective in alleviating perihematomal edema and neurologic deficits in patients with intracranial hemorrhage.

Timeline

Start
2016-06
Primary completion
2017-12
Completion
2018-04

Drugs

EvaluationDrugModalityDoseRoute
Subject Immune Globulin Intravenous (Human) Protein / enzyme biologic 0.4 g/kg Intravenous